Dual-Driver Myeloproliferative Neoplasm: Concurrent p190 BCR::ABL1 CML and JAK2 V617F Mutation: A Case Report and Literature Review. (PubMed, Case Rep Hematol) - Sep 25, 2026 - "The patient received first-line asciminib and was subsequently transitioned to dasatinib, with the BCR::ABL1/ABL1 ratio declining from 88.5% at diagnosis to 0.79% at most recent assessment. The admixed megakaryocytic atypia superimposed on myeloid hyperplasia reflected the coexistence of two drivers. Comprehensive profiling, including high-sensitivity RT-PCR capable of detecting the p190 isoform and concurrent JAK2 testing, is essential for accurate diagnosis, prognostication, and therapy selection in these rare dual-driver cases."
Journal • Chronic Myeloid Leukemia • Essential Thrombocythemia • Fibrosis • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Myeloproliferative Neoplasm • Oncology • Thrombocytopenia • Thrombocytosis • ABL1 • BCR • JAK2
|
|
Mohamed Elkady; Weiqiang Zhao; Yulan Jin
|